Bach Griera, MarcCampo Pérez, VíctorBarbosa, SandraTraserra, SaraGuallar Garrido, SandraMoya Andérico, LauraHerrero Abadía, PaulaLuquin, MarinaRabanal Prados, Rosa Ma. (Rosa Maria)Torrents Serra, EduardJulián, Esther2021-02-252021-02-252020-04-252076-393Xhttps://hdl.handle.net/2445/174370Intravesical Mycobacterium bovis Bacillus Calmette-Guérin (BCG) immunotherapy remains the gold-standard treatment for non-muscle-invasive bladder cancer patients, even though half of the patients develop adverse events to this therapy. On exploring BCG-alternative therapies, Mycolicibacterium brumae, a nontuberculous mycobacterium, has shown outstanding anti-tumor and immunomodulatory capabilities. As no infections due to M. brumae in humans, animals, or plants have been described, the safety and/or toxicity of this mycobacterium have not been previously addressed. In the present study, an analysis was made of M. brumae- and BCG-intravenously-infected severe combined immunodeficient (SCID) mice, M. brumae-intravesically-treated BALB/c mice, and intrahemacoelic-infected-Galleria mellonella larvae. Organs from infected mice and the hemolymph from larvae were processed to count bacterial burden. Blood samples from mice were also taken, and a wide range of hematological and biochemical parameters were analyzed. Finally, histopathological alterations in mouse tissues were evaluated. Our results demonstrate the safety and non-toxic profile of M. brumae. Di erences were observed in the biochemical, hematological and histopathological analysis between M. brumae and BCG-infected mice, as well as survival curves rates and colony forming units (CFU) counts in both animal models. M. brumae constitutes a safe therapeutic biological agent, overcoming the safety and toxicity disadvantages presented by BCG in both mice and G. mellonella animal models.18 p.application/pdfengcc-by (c) Bach Griera, Marc et al., 2020http://creativecommons.org/licenses/by/3.0/esÀcids grassosCàncerFatty acidsCancerMycolicibacterium brumae is a safe and non-toxic immunomodulatory agent for cancer treatmentinfo:eu-repo/semantics/article7018032021-02-25info:eu-repo/semantics/openAccess32344808